Match!

Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series.

Published on Sep 1, 2012in International Journal of Clinical Practice2.613
· DOI :10.1111/j.1742-1241.2012.02981.x
T. Adizie1
Estimated H-index: 1
,
D. Christidis1
Estimated H-index: 1
+ 2 AuthorsBhaskar Dasgupta35
Estimated H-index: 35
(University of Essex)
Abstract
Summary Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are related inflammatory rheumatic conditions affecting adults over the age of 50 years. Both conditions respond to initial glucocorticoid (GC) therapy. However, most patients require 12–36 months of a tapering steroid regime. Adverse events at 2 years are seen in up to 65% of patients with PMR and 86% of patients with GCA with over 50% developing serious events. There is also a high incidence of relapse in both diseases −40% within 2 years for GCA and 50% of patients with PMR at some point having a relapse. Effective steroid-sparing adjuvant therapies are urgently required especially in incomplete, poorly sustained or non-responders to glucocorticoids. In this case series, we found that Leflunomide is efficacious, with 22 out of our 23 patients exhibiting a complete or partial response. It was also steroid sparing and well tolerated. It may be a useful adjunctive agent in difficult-to-treat GCA and PMR. Prospective randomised controlled trials of Leflunomide in both GCA and PMR are now required.
  • References (18)
  • Citations (54)
📖 Papers frequently viewed together
319 Citations
247 Citations
383 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References18
Newest
#1Julien VinitH-Index: 7
#2P. BielefeldH-Index: 9
Last. J.F. BesancenotH-Index: 10
view all 4 authors...
Abstract Giant cell arteritis is the most frequent form of vasculitis characterized by a high risk of vascular thrombosis. Major complications are blindness and other vascular ischemia but bowel ischemic involvement is rare. Treatment is based on long-term steroid therapy with numerous side effects. The efficacy of immunosuppressive drugs like azathioprine methotrexate or anti-tumor necrosis factor antibodies appears to be too low to reduce the use of steroids. Th17 lymphocytes and interleukin-6...
40 CitationsSource
#1Friederike KestenH-Index: 4
#2Markus AschwandenH-Index: 26
Last. Christoph HessH-Index: 31
view all 6 authors...
Summary Giant cell arteriitis (GCA) is the most common of the vasculitis syndromes and, being a disease of the elderly, its incidence is increasing with the general ageing of the population. GCA is most feared for its early complications, namely blindness and stroke, resulting from inflammation and subsequent occlusion of ocular and extra cranial arteries, respectively. More recently, however, GCA has been recognised to also affect limb arteries and the aorta with a high prevalence. These newly ...
13 CitationsSource
#1Bhaskar Dasgupta (Lond: University of London)H-Index: 35
#2Frances A. Borg (Lond: University of London)H-Index: 6
Last. Ash Samanta (Lond: University of London)H-Index: 2
view all 14 authors...
Scope and purpose GCA is the commonest of all the vasculitides. Visual loss occurs in up to one-fifth of patients, which may be preventable by prompt recognition and treatment [1,2]. The aim of these guidelines is to encourage the prompt diagnosis and management of GCA, with emphasis on the prevention of visual loss. Their scope is to provide evidence-based advice for the assessment and diagnosis of GCA, for initial and further management and for monitoring of disease activity, complications and...
246 CitationsSource
#1Bhaskar Dasgupta (Lond: University of London)H-Index: 35
#2Frances A. Borg (Lond: University of London)H-Index: 6
Last. Ash Samanta (Lond: University of London)H-Index: 2
view all 11 authors...
PMR is the most common inflammatory rheumaticdisease in the elderly and is one of the biggest indicationsfor long-term steroid therapy. There are difficulties indiagnosis, with heterogeneity in presentation, responseto steroids and disease course.The aim of these guidelines is a safe and specificdiagnostic process for PMR, using continued assessment,and discouragement of hasty initial treatment. Their scopeis to provide advice for the diagnosis of PMR, manage-ment and monitoring of disease activ...
147 CitationsSource
#2Maria C. CidH-Index: 52
Last. Xavier Bosch XH-Index: 49
view all 5 authors...
Background Polymyalgia rheumatica (PMR) treatment is based on low-dose glucocorticoids. Glucocorticoid-sparing agents have also been tested. Our objective was to systematically examine the peer-reviewed literature on PMR therapy, particularly the optimal glucocorticoid type, starting doses, and subsequent reduction regimens as well as glucocorticoid-sparing medications. Methods We searched Cochrane Databases and MEDLINE (1957 through December 2008) for English-language articles on PMR treatment ...
78 CitationsSource
#1Fengmin Zhang (HMU: Harbin Medical University)H-Index: 10
#2Y. K. Nie (HMU: Harbin Medical University)H-Index: 1
Last. Y. Sun (HMU: Harbin Medical University)H-Index: 1
view all 6 authors...
To evaluate the clinical and pathological efficacy, and safety of leflunomide as a new immunosuppressive medicine in lupus nephritis (LN). A total of 31 patients were all determined as LN by kidney biopsy. SLE disease activity index (SLEDAI), clinical and immunological tests of these patients were performed. Meanwhile, the pathological presentation and LN activity of before and after leflunomide therapy were evaluated by repeat biopsy. The patients of LN usually have a bit response by the first ...
23 CitationsSource
#1Víctor M Martínez-Taboada (UC: University of Cantabria)H-Index: 30
#2Lorena Alvarez (UC: University of Cantabria)H-Index: 3
Last. Marcos López-Hoyos (UC: University of Cantabria)H-Index: 27
view all 5 authors...
Abstract Objective: To summarize the contribution of cytokines to pathogenesis, clinical manifestations and prognosis of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). Methods: MEDLINE database search for studies published between 1980 and April 2008. Results: PMR and GCA are characterized by a hyperproduction of IL-6. The role of other circulating cytokines in their pathogenesis remains unclear. Cytokine mRNA in the arterial wall of GCA can distinguish different clinical subgroups...
62 CitationsSource
#1Bhaskar Dasgupta (Southend University Hospital NHS Foundation Trust)H-Index: 35
#2Carlo SalvaraniH-Index: 70
Last. Eric Lawrence Matteson (Mayo Clinic)H-Index: 70
view all 7 authors...
OBJECTIVE: This report summarizes the findings from a consensus process to identify potential classification criteria for polymyalgia rheumatica (PMR). METHODS: A 3-stage hybrid consensus approach was used to develop potential PMR classification criteria. The first stage consisted of a facilitated meeting of 27 international experts who anonymously rated the importance of 68 potential criteria. The second stage involved a meeting of the experts, who were provided with the results of the first ro...
74 Citations
#1V S SangleH-Index: 1
#2S R SangleH-Index: 1
Last. D P D’CruzH-Index: 1
view all 3 authors...
Dermatomyositis (DM) is an autoimmune disorder affecting skeletal muscles and skin with a female preponderance.1 Classification for DM by Bohan and Peter is still in use today.2 A 54-year-old woman presented with a facial rash, joint pains, generalised weakness and breathlessness. Clinically she had Gottron’s sign, mechanic’s hands, a heliotropic rash and weakness in her quadriceps grade 3 and neck muscles grade 4, on a five-point system. She had raised creatinine kinase (CK) >3000 u/l (normal 2...
17 CitationsSource
#1Metzler CH-Index: 9
#2N. Miehle (HHU: University of Düsseldorf)H-Index: 1
Last. Eva Reinhold-KellerH-Index: 31
view all 8 authors...
Objectives. Results from open-label trials suggest that methotrexate (MTX) and leflunomide (LEF) are effective for maintenance of remission in Wegener’s granulomatosis (WG), but data from randomized controlled clinical trails are not yet available. Methods. In this multicentre, prospective randomized controlled clinical trial, patients with generalized WG were treated either with oral LEF 30 mg/day or oral MTX (starting with 7.5 mg/week reaching 20 mg/week after 8 weeks) for 2 yrs following indu...
157 CitationsSource
Cited By54
Newest
#1Tal Gazitt (UW: University of Washington)
#2Devy ZismanH-Index: 15
Last. Gregory C. Gardner (UW: University of Washington)H-Index: 12
view all 3 authors...
PURPOSE OF THE REVIEW Polymyalgia rheumatica (PMR) is one of the most common inflammatory rheumatologic condition occurring in older adults. It is characterized by proximal pain and stiffness in the shoulders, neck, and/or pelvic girdle in individuals over 50 years of age along with evidence of an intense systemic inflammatory response. Although the above clinical symptoms are very characteristic for the condition, it can be mimicked by other autoimmune, infectious, malignant, and endocrine diso...
Source
#1Sarah L. Mackie (University of Leeds)H-Index: 19
#2Christian Dejaco (University of Graz)H-Index: 27
Last. Alexandre Wagner Silva de Souza (UNIFESP: Federal University of São Paulo)H-Index: 13
view all 36 authors...
4 CitationsSource
#1Bernhard Hellmich (University of Tübingen)H-Index: 35
#2Ana Filipa ÁguedaH-Index: 3
Last. Raashid Luqmani (University of Oxford)H-Index: 53
view all 26 authors...
Background Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical trials and cohort analyses have been published, which have the potential to change clinical care and therefore supporting the need to update the original recommendations. Methods Using EULAR standardised operating procedures for EULAR-endorsed recommendations, the EULAR task force undertook a systemati...
48 CitationsSource
#1Hannah Lyons (University of Birmingham)H-Index: 1
#2Vanessa QuickH-Index: 1
Last. Susan P. MollanH-Index: 12
view all 5 authors...
The landscape of the investigation and management of giant cell arteritis (GCA) is advancing. In this review we will outline the recent advances by searching the current English literature for relevant articles using key words of giant cell arteritis, temporal arteritis, Horton’s disease, investigation, and treatment. Delay in diagnosis, diagnostic uncertainty and glucocorticoid (GC) morbidity are among the highest concerns of clinicians and patients in this disease area. The positive news is th...
2 CitationsSource
#1J.L. Leung (University of Melbourne)
#1Jessica L. Leung (University of Melbourne)
Last. David Liew (University of Melbourne)H-Index: 2
view all 4 authors...
Source
#1Sara MontiH-Index: 9
#2Ana Filipa ÁguedaH-Index: 3
Last. Bernhard HellmichH-Index: 35
view all 11 authors...
Objectives To analyse the current evidence for the management of large vessel vasculitis (LVV) to inform the 2018 update of the EULAR recommendations. Methods Two systematic literature reviews (SLRs) dealing with diagnosis/monitoring and treatment strategies for LVV, respectively, were performed. Medline, Embase and Cochrane databases were searched from inception to 31 December 2017. Evidence on imaging was excluded as recently published in dedicated EULAR recommendations. This paper focuses on ...
2 CitationsSource
#1Maxime Samson (French Institute of Health and Medical Research)H-Index: 17
#2Hélène Greigert (French Institute of Health and Medical Research)
Last. Bernard Bonnotte (French Institute of Health and Medical Research)H-Index: 33
view all 4 authors...
Points essentiels En 2019, la corticotherapie reste le traitement de reference de l’arterite a cellules geantes (ACG) mais a condition de respecter des valeurs seuils concernant la decroissance des doses : 15 a 20 mg/j a 3 mois, 10 mg/j a 6 mois, 5 mg/j a 9–12 mois et sevrage en 12 a 18 mois. En cas de corticodependance a plus de 7,5 mg/j de prednisone ou d’intolerance de la corticotherapie, un traitement d’epargne en corticoides doit etre instaure, en premiere intention, methotrexate ou tociliz...
Source
#1S Tengesdal (Hospital of Southern Norway)H-Index: 1
Last. G. Myklebust (Hospital of Southern Norway)H-Index: 7
view all 3 authors...
1 CitationsSource
#1Santos Castañeda (UAM: Autonomous University of Madrid)H-Index: 32
#2Noelia García-Castañeda (UAM: Autonomous University of Madrid)H-Index: 1
Last. Miguel A. González-Gay (UC: University of Cantabria)H-Index: 10
view all 7 authors...
Abstract Polymyalgia rheumatica (PMR) is an inflammatory disease characterized by bilateral pain involving predominantly the shoulders and proximal aspects of the arms and less commonly the neck and the pelvic girdle. This review discusses briefly the main epidemiological data and clinical features of this condition. Especial attention is paid in the management of the disease. For this reason, both the classic management and the impact of new therapies are discussed in depth. In general, patient...
1 CitationsSource
#1Alia Z. Al-MousawiH-Index: 1
#2Sam P. GurneyH-Index: 1
Last. Susan P. MollanH-Index: 1
view all 6 authors...
Improving understanding of the underlying pathophysiology of giant cell arteritis (GCA) is transforming clinical management by identifying novel avenues for targeted therapies. One key area of concern for both clinicians and patients with GCA is glucocorticoid (GC) morbidity. The first randomised controlled trials of targeted treatment to reduce cumulative GC use in GCA have been published, with tocilizumab, an interleukin (IL)-6 receptor inhibitor, now the first ever licensed treatment for GCA....
2 CitationsSource